AMGN - Amgen Inc.
| Previous close | 222.14 |
| Open | 222.24 |
| Bid | 218.14 x 800 |
| Ask | 223.61 x 900 |
| Day's range | 220.99 - 223.80 |
| 52-week range | 166.30 - 244.99 |
| Volume | 2,047,484 |
| Avg. volume | 2,193,827 |
| Market cap | 131.403B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | 17.30 |
| EPS (TTM) | 12.88 |
| Earnings date | 27 Apr 2020 - 03 May 2020 |
| Forward dividend & yield | 6.40 (2.88%) |
| Ex-dividend date | 12 Feb 2020 |
| 1y target est | 246.05 |
- Reuters - UK Focus
Pharmaceutical companies develop system to better track counterfeit drugs
Some of the industry's largest pharmaceutical companies, including Pfizer Inc and Eli Lilly and Co, have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines, company officials said on Friday. Some two dozen companies in the industry including drugmakers, distributers, retailers and delivery firms created the blockchain-based MediLedger Network, which it has been testing in the verification of drug returns. Blockchain, which first emerged as the technology underlying virtual currency bitcoin, is a shared database maintained by a network of computers.
- Reuters
Coronavirus outbreak begins to disrupt booming China drug trials
The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc. China has imposed a virtual lockdown on Wuhan and severely restricted travel in its wider province of Hubei and some other cities.
- Reuters - UK Focus
FOCUS-Coronavirus outbreak begins to disrupt booming China drug trials
The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.
- Zacks
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
- Zacks
J&J Files Application for Darzalex Label Expansion With FDA
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
- Simply Wall St.
If You Had Bought Amgen (NASDAQ:AMGN) Shares Five Years Ago You'd Have Made 47%
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
- Zacks
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
- Zacks
Top Stock Research Reports for Alphabet, Roche & Amgen
Top Stock Research Reports for Alphabet, Roche & Amgen
- Zacks
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
- Zacks
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
- Zacks
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
- Zacks
Sanofi (SNY) Q4 Earnings Top, Sales Miss, Dupixent Strong
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
- Investing.com
Amgen Stock Rises 6%
Investing.com - Amgen (NASDAQ:AMGN) Stock rose by 5.52% to trade at $234.04 by 14:02 (19:02 GMT) on Wednesday on the NASDAQ exchange.
- Zacks
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
- Zacks
KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day
KB Home, National Beverage, Amazon, Visa and Amgen highlighted as Zacks Bull and Bear of the Day
- Investing.com
Amgen Stock Falls 3%
Investing.com - Amgen (NASDAQ:AMGN) Stock fell by 3.42% to trade at $218.37 by 09:30 (14:30 GMT) on Friday on the NASDAQ exchange.
- Zacks
Amgen (AMGN) Stock Down Despite Q4 Earnings & Revenue Beat
Amgen (AMGN) stock declines despite better-than-expected fourth-quarter 2019 results. Its 2020 earnings guidance falls short of expectations.
- Zacks
Amazon Beats Big on Q4 Bottom Line; Plus V, AMGN
Expectations for Q4 earnings were on the low side, both at Zacks and on the street, so take this giant bottom-line beat with a grain of salt.
- Reuters
Amgen 2020 outlook falls short of Street estimates; shares slump
The difference is largely due to lower interest income and anticipated accounting for the recently acquired 20.5% stake in China's BeiGene Ltd , Amgen's chief financial officer, Peter Griffith, said on a conference call. For the fourth quarter of last year, Amgen said product sales fell 2% from a year earlier due to competition from lower-cost generic drugs and biosimilars, but share buybacks reduced the number of shares outstanding, enabling the company to post a per-share profit that topped Wall Street estimates.
- Zacks
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
Amgen (AMGN) delivered earnings and revenue surprises of 5.81% and 3.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Q4 GDP 2.1%, In-Line with Q3; Plus Q4 Earnings from VZ, KO & More
Q4 GDP hit the tape ahead of today's opening bell, with results better than analysts had been predicting: +2.1% was 30 basis points higher than the 1.8% expected.
